
|Videos|August 30, 2022
Selecting an Effective Treatment Approach Informed by Recent mCSPC Research
Author(s)Marc Matrana, MD
Clinical insights concerning the selection of effective treatment approaches for patients with mCSPC with comments on the study design and results of the TITAN study.
Advertisement
Episodes in this series

Advertisement
Related to this article

Updated LEGEND trial data show durable responses with detalimogene in BCG-unresponsive NMIBC, supporting a planned BLA submission by year-end 2026.

The FDA issued a complete response letter to the biologics license application for ivonescimab for use in combination with chemotherapy in EGFR-mutated NSCLC.

Crossover to bezuclastinib plus sunitinib after progression on sunitinib improved PFS and responses in GIST in phase 3 PEAK, with no new safety signals.

Arvind Dasari, MD, MS, explains how to sequence radioligand therapy, cabozantinib, and everolimus in well-differentiated neuroendocrine tumors.

A survey of US veterans with non-muscle invasive bladder cancer identifies barriers to treatment access, care coordination challenges, and gaps in patient education.

The perioperative regimen improved event-free and overall survival in the phase 3 VOLGA trial, offering a new option for patients with muscle-invasive bladder cancer who cannot receive or decline cisplatin.

Ravi Parikh, MD, MPP, discusses the future of oncology practice, including real-world data, patient engagement, emerging technologies, and policy priorities shaping cancer care.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Does Not Approve Ivonescimab for EGFR-Mutant NSCLC
2
Dr Dasari on Sequencing RLT, Cabozantinib, and Everolimus in NETs
3
Crossover to Bezuclastinib Plus Sunitinib Improves Disease Control in Pretreated GIST
4
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
5
